Company Overview of BiPar Sciences, Inc.
BiPar Sciences, Inc., a biopharmaceutical company, develops tumor-selective drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded in 2002 and is headquartered in Brisbane, California. As of April 27, 2009, BiPar Sciences, Inc. operates as a subsidiary of Sanofi.
1000 Marina Boulevard
Brisbane, CA 94005
Founded in 2002
Key Executives for BiPar Sciences, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact BiPar Sciences, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.